Not Yet RecruitingN/ALSD
Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Sponsored by Northern Jiangsu People's Hospital
NCT ID
NCT07585786
Target Enrollment
30 participants
Start Date
2026-05-01
Est. Completion
2029-02-28
About This Study
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .
Conditions Studied
Eligibility
Age:18 Years - 80 Years
View full eligibility criteria
Inclusion Criteria: 1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging) 2. Splenomegaly and hypersplenism 3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding ) 4. Age 18-80 years, male or female 5. Child-Pugh Class A or B liver function 6. No history of primary renal disease or acute kidney injury (AKI) 7. Signed written informed consent 8. Ability to complete 24-month follow-up Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis 2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.) 3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection 4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders 5. Hepatic encephalopathy or refractory ascites within 1 month before surgery 6. Pregnancy or lactation 7. Poor compliance, inability to complete follow-up